AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02806375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Description: Days -7 through -2: 30 mg/m2/day iv qd x 6 days
Study NCT02806375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day +3 and +4: 50 mg/kg/day iv qd
Study NCT02806375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Days -8 through -2 15 mg tid
Study NCT02806375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Days +5 through +100: 7.5 mg bid
Study NCT03479320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Postoperative analgesic effects will be compared between lidocaine and normal saline group
Study NCT03479320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Postoperative anlagesic requirements will be calculated and compared with experimental group
Study NCT04240366 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control intervention
Description: patients treated with balloon-based ablation of AF by PVI
Study NCT04240366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Description: patients treated with balloon-based ablation of AF by PVI
Study NCT01302847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG film-coated tablets
Description: DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
Study NCT01302847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG granules for suspension
Description: DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
Study NCT01302847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG dispersible tablets
Description: DTG dispersible tablets initial starting dose of \~0.8 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets.
Study NCT01302847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG dispersible tablets
Description: DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets.
Study NCT01302847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG dispersible tablets
Description: DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets.
Study NCT04630431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care follow-up
Study NCT04630431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo standard of care follow-up
Study NCT04630431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Undergo clinical trial education via a video and educational booklet
Study NCT04630431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo clinical trial education via a video and educational booklet
Study NCT04630431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Review of medical record
Study NCT04630431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Review of medical record
Study NCT04630431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Undergo clinical trial navigation
Study NCT04630431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT04630431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT02180061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03623256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal fentanyl
Description: 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
Study NCT03623256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal bupivacaine
Description: 1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.
Study NCT03623256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Fentanyl and Bupivacaine
Description: 1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
Study NCT03623256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl /spinal bupivacaine
Description: 1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
Study NCT02539563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peanut shaped birthing ball
Description: peanut ball will be utilized
Study NCT01429402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
Study NCT01429402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Type A
Description: b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
Study NCT01429402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
Study NCT01429402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
Study NCT03804645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
Study NCT03777436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study NCT03996005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
Description: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
Study NCT02798380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTS-519 Insert
Description: Maximum feasible dose of HTS-519 Insert per diseased nail
Study NCT04089904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Patients will receive 3 cycles of pembrolizumab at 200mg intravenously on day 1 of a 3 week cycle. After 3 cycles the patients will undergo surgery
Study NCT01903330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERC1671
Description: Given intradermally
Study NCT01903330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Given intradermally
Study NCT01903330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
Study NCT01903330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Control (Sucrose pill)
Description: Given PO
Study NCT01903330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))
Description: Given IV
Study NCT01903330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab/Bevacizumab Biosimilar
Description: Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
Study NCT01903330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab/Bevacizumab Biosimilar
Description: Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
Study NCT01343680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 5ml 10 units/ml IV heparin 3 times per week
Study NCT01343680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 10ml normal saline IV weekly
Study NCT02882581 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-metformin
Description: 400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
Study NCT04008719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thymic history
Description: This interview concerns mainly the nature of the previous psychiatric and psychological care
Study NCT04008719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the psychiatric disorders
Description: Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.
Study NCT04008719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive evaluation
Description: They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.
Study NCT01557374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab, Abatacept
Description: Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week
Study NCT01557374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decrease Tocilizumab, Abatacept
Description: The decrease pattern is established on 4 consecutive stages :~IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):~Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop~SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):~Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop~* If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.~* If DAS 28 > 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage~* If DAS 28 > 3,2 : return to previous stage, (relapse according to European expert consensus)~In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study.
Study NCT04026074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo salve
Description: Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
Study NCT00348283 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adalimumab
Description: At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
Study NCT00348283 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
Study NCT03804645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
Study NCT03804645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.
Study NCT00348283 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: adalimumab
Description: At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
Study NCT00515281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inhaled nitric oxide
Description: The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
Study NCT03804645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
Study NCT00515281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
Study NCT00515281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
Study NCT04281875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRAF Detection Technology
Description: Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio > 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.
Study NCT02481349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care
Study NCT02481349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive DVD for home practice
Study NCT02481349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02481349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02481349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02481349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02481349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Complete couple-based Hatha yoga program
Study NCT01765439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3 (Original De Simone formulation)
Description: Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
Study NCT03443752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shotokan-Karate
Description: The Shotokan-Karate training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
Study NCT03443752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai-Chi
Description: The Tai-Chi training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
Study NCT01145547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom Seven® Plus Continuous Glucose Monitoring sensor
Description: A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.
Study NCT01018576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Description: Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
Study NCT01770314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
Study NCT03093597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virgin coconut oil
Description: One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin coconut oil application twice daily for 2 weeks.
Study NCT03093597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virgin jojoba oil
Description: One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin jojoba oil application twice daily for 2 weeks.
Study NCT03093597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virgin almond oil
Description: One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin almond oil application twice daily for 2 weeks.
Study NCT03093597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: white petrolatum ointment
Description: One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive white petrolatum ointment application twice daily for 2 weeks.
Study NCT00688051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Life with CF game
Description: Play the game My Life with CF
Study NCT02145195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Study NCT04140422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperosmolar eye drops
Description: Application of one preservative-free hyperosmolar eye drop, when waking up and one eye drop 30 min later to one eye by the investigators